Expanding The Therapeutic Versatility Of Clascoterone

Clascoterone (cortexolone 17α-propionate) cream 1% is a topical treatment for acne vulgaris in patients aged 12 and above, approved in the United States in August 2020. It is believed to work by competing with dihydrotestosterone for androgen receptors located in pilosebaceous units, thereby inhibiting the acnegenic downstream effects of dihydrotestosterone such as lipid synthesis and inflammatory cytokine production in a dose-dependent manner. Its safety profile is similar to placebo regarding systemic antiandrogenic effects. This treatment could potentially be used for other androgen-influenced disorders such as hidradenitis suppurativa and androgenetic alopecia.